Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 15;14:1443. doi: 10.1038/s41467-023-37147-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 7 — a Log2 relative growth rates of #5346 PDAC cells pre-treated with Ad-Cre (Tm+Yap−) or Ad-GFP (GFP+Yap+) co-cultured over a 2-month period in the presence of indicated epigenetic inhibitors normalized to DMSO. BET inhibitors are highlighted in red. b Log2 relative growth rates of Yap− relative to Yap+ cells in primary PDAC lines treated for 6 days with BET inhibitor ABBV-075 (+) or DMSO control (−). Primary PDAC lines are grouped based on PTF score (left) and differentiation status (right). Left panel: n = 12 and 5 independent cell lines for the Low (0–2) and High (3–5) PTF groups, respectively. Right panel: n = 7, 6, and 4 for EP, Int, and MS groups, respectively. Unpaired, two-tailed, Student’s t-test. Data are presented as mean value ± SEM. c Dose−response matrixes generated by SynergyFinder of ABBV plus Yap/Tead inhibitor VT103 in mT3 (Loewe synergy score = 31.7) and mT4 (Loewe synergy score = 30.7) PDAC cells derived from KrasG12D/+:Trp52R172H/+:Pdx-Cre (KPC) mice. d, e Changes in relative tumor size of mT4 (d) and #5462 (e) xenografts treated with ABBV (light blue), VT103 (blue), ABBV + VT103 (pink), or DMSO (black). N = 6 mice for each treatment arm. Data are presented as mean value ± SEM. Two-way ANOVA test. f Western blot analysis of indicated proteins in the indicated PTF-expressing primary PDAC lines treated with ABBV or DMSO. Vinc was used as the loading control. Shown is representative of three independent experiments. Source data are provided within a Source Data file.